BE COMPLETE study: Bimekizumab (IL-17A and IL-17F inhibitor) efficacious in phase 3 trial for treatment of PsA. No new safety signals. Abs#1599 @RheumNow #ACR22 https://t.co/iXj7wSRNeK

Abs 1507 at #ACR22 demonstrated that even a 6-month delay in PsA dx from symptom onset contributes to worse patient-reported outcomes measures on overall quality of life. @RheumNow https://t.co/qLOwE9rImz https://t.co/nacdjz5pCy

• Diagnostic Delay of More Than 6 Months Contributes to Poor Patient-Reported Out…

The likelihood of a patient self-reporting LDA/REM and specificity of MDA score were unaffected by which MDA criteria were met. @DrLauraCoates et al, Abs 1496 #ACR22 @RheumNow https://t.co/xH70swdZZ0 https://t.co/Wct0emTaDt

• Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA C…

#Abs1260 #acr22 @rheumnow #acrbest Clincial&US eval 54 RA &18 PsA pts: Tenderness aasoctd w/radiographic progress in non-swollen jnts in PsA but not in RA. In tender non-swollen jnts in RA pts, baseline erosions& sonographic synovitis had significant impact on radio progression https://t.co/iqWvHiDeq8

RZB is efficacious in reducing signs and symptoms of PsA in patients, regardless of patterns of joint involvement Abs 1504 #ACR @AlexisOgdie @RheumNow https://t.co/AIEJbqrqBf https://t.co/kyiocs8TmL

• Efficacy of Risankizumab in the Treatment of PsA Patients with Limited and Exte…

Sonographic enthesitis is assoc'd w/ sonographic synovitis and tenosynovitis in PsA. Abs 1498 #ACR22 @RheumNow https://t.co/tssYZ55iMq https://t.co/C7Dk66rwVA

• The Association Between Sonographic Enthesitis with Sonographic Synovitis and T…

Delay in AS dx appeared to be BMI-dependent in female pts and both genders n PsA dx. In contrast to AS, SEC treatment response of early- and late-diagnosed PsA pts did not differ. Abs 1497 #ACR22 @RheumNow https://t.co/LBo3XapAT4 https://t.co/uAcfeiED4F

• How Does Time to Diagnosis and Gender Affect Treatment Outcomes in Patients wit…

#abs1235 #acr22 @rheumnow articular fibroblast activation in PSO assessed by 68Ga-FAPI-04 PET-CT assoctd w/⬆️ risk of developing PsA. 10 pts assessed: 6/7 pts (85.7%)w/ 68Ga-FAPI-04 uptake at synovio-entheseal sites progressed to PsA. median PsA-free time 207 (160-240)days https://t.co/Y6EHPaDwfh

PsA pts starting 1st DMARD tx, both early & late initiators experienced dz activity and PRO improvements up to 6 months post-initiation. Better response, including MDA, achieved in pts initiating DMARD tx w/in 1 yr of dx. Abs 1493 #ACRbest #ACR22 @RheumNow https://t.co/a94sZRQ3VF https://t.co/OSUEoChtFf

• Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs…

🌟PSA vs RA 🌟 -UK cohort PSA associated with: 👉⬆️ duration symptoms prior 2 referral 👉⬆️ interval between GP presentation and DX 👉⬇️DMARD commencement 👉⬇️ improvement in Dx activity @ 3/12 # We need to do better #ACR22 Abst#1613 @RheumNow

There is an association between the severity of skin and joint or axial disease, both at baseline and longitudinally, in pts presenting w/in 12 months of diagnosis of PsA. Abs 1511 #ACR22 @RheumNow https://t.co/PcVn6dITqU https://t.co/qxn3LBOW8d

• Is There a Correlation Between Skin and Musculoskeletal Activity in Psoriatic A…

Even a 6 month delay in PsA diagnosis can lead to worse PROs on quality of life! Likelihood of depression increased Pts with PsA dx in <6 months reported better outcomes Abs#1507 @RheumNow #ACR22 https://t.co/igCiH22CWi

GUS (compared to RIS) uniquely binds both CD64+ myeloid cells and IL-23. CD64+ mononuclear phagocytes are enriched in the psoriatic skin and serve as the dominant IL-23 source. Does this lead to a change in clinical response? Abs 1487 #ACR22 @RheumNow https://t.co/P512bxSxRn

• Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23 - ACR M…

‼️FAP (fibroblast activation protein) PET-CT in PsA‼️ ⚡️synovial and entheseal accum in PsA v HC ⚡️correlation of uptake with pain scores ⚡️IL-17A ⬇️ FAP, with arrest joint damage ⚡️persistent FAP - ⬆️ prog joint damage ❓new T2T in PsA❓ #ACR22 @RheumNow Abst#1602